BRAF V600E + PIK3CA mutation
|
CRC
|
BRAF V600E + PIK3CA mutation
|
CRC
|
cetuximab + alpelisib + encorafenib Resistant: C3 – Early Trials
|
cetuximab + alpelisib + encorafenib Resistant: C3 – Early Trials
|
BRAF V600E + PIK3CA mutation
|
CRC
|
BRAF V600E + PIK3CA mutation
|
CRC
|
cetuximab + encorafenib + binimetinib Resistant: C3 – Early Trials
|
cetuximab + encorafenib + binimetinib Resistant: C3 – Early Trials
|
BRAF V600E + PIK3CA mutation
|
CRC
|
BRAF V600E + PIK3CA mutation
|
CRC
|
cetuximab + encorafenib Resistant: C3 – Early Trials
|
cetuximab + encorafenib Resistant: C3 – Early Trials
|
BRAF V600E + PIK3CA mutation
|
Astrocytoma
|
BRAF V600E + PIK3CA mutation
|
Astrocytoma
|
vemurafenib + everolimus Sensitive: C4 – Case Studies
|
vemurafenib + everolimus Sensitive: C4 – Case Studies
|